Today: 23 April 2026
Subscribe
Browse Category

NYSE:ORLY 9 December 2025

Stock Market Today

  • Pitney Bowes (PBI) Upgraded to Zacks Rank #2 Buy on Rising Earnings Forecasts
    April 23, 2026, 1:35 PM EDT. Pitney Bowes (PBI) has been upgraded to a Zacks Rank #2 (Buy) driven by an upward revision in earnings estimates, highlighting improved expectations for the company's future profits. The Zacks Rank system, which reflects changes in consensus earnings per share (EPS) estimates from analysts, correlates strongly with near-term stock price movements. Institutional investors often adjust valuations based on these earnings revisions, influencing stock price trends. Pitney Bowes' anticipated EPS of $1.52 for fiscal 2026 underlines positive business momentum. The upgrade suggests investors may see buying opportunities as earnings outlooks improve, reinforcing the value of tracking earnings estimate revisions in stock selection.

Latest article

US Stock Market Today: S&P 500, Nasdaq Stall Near Records as Oil Above $100 Clouds Wall Street

US Stock Market Today: S&P 500, Nasdaq Stall Near Records as Oil Above $100 Clouds Wall Street

23 April 2026
The S&P 500 and Nasdaq slipped from record highs by late morning Thursday, with the Dow down 99.59 points, or 0.20%. Brent crude traded above $103 a barrel as Strait of Hormuz disruptions persisted. IBM, Tesla, and Lockheed Martin fell after earnings, while Texas Instruments surged 18.4%. Weekly U.S. jobless claims rose to 214,000; business activity expanded but inflation pressures remained.
IREN Stock Jumps as AI Cloud Bet Meets $6 Billion Dilution Test

IREN Stock Jumps as AI Cloud Bet Meets $6 Billion Dilution Test

23 April 2026
IREN shares jumped 7.3% to $51.94 in New York Thursday amid debate over its shift from bitcoin mining to AI cloud services. The company plans to deploy 150,000 Nvidia GPUs by late 2026 and reported $2.8 billion in cash as of January. AI cloud revenue remains small compared to bitcoin mining, with $17.3 million last quarter. IREN can sell up to $6 billion in stock under a new SEC filing.
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

23 April 2026
Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
Go toTop